title: Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
abstract: In the coming years, genomics will impact clinical practice in multiple ways. However, one of the most important applications will be in the determination of the best treatments in personalized medicine. This is, in fact, one of the fields in which genetic variants have already been most successful and useful to clinicians. Here, we briefly review the current state of the art on pharmacogenomics and its applications to modern cardiovascular medicine.
authors.affiliation: Center for Human Genetics research, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, 511 Light Hall, 2215 Garland Avenue, Nashville, TN 37232, USA. Irene.m.predazzi@vanderbilt.edu
authors.forename: Irene M
authors.initials: IM
authors.lastname: Predazzi
authors.forename: Ruggiero
authors.initials: R
authors.lastname: Mango
authors.forename: Giuseppe D
authors.initials: GD
authors.lastname: Norata
authors.forename: Nicola
authors.initials: N
authors.lastname: Di Daniele
authors.forename: Domenico
authors.initials: D
authors.lastname: Sergi
authors.forename: Francesco
authors.initials: F
authors.lastname: Romeo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Novelli
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010597:Pharmacogenetics / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D057285:Precision Medicine / Q000379:methods*; D014859:Warfarin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin